OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
Matteo Perrino, Fabio De Vincenzo, Nadia Cordua, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Matteo Perrino, Fabio De Vincenzo, Nadia Cordua, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Showing 13 citing articles:
Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy
Yuanfeng Zhang, Juanjuan Wu, Chaobin Zhao, et al.
Journal of Cancer (2023) Vol. 14, Iss. 5, pp. 850-873
Open Access | Times Cited: 16
Yuanfeng Zhang, Juanjuan Wu, Chaobin Zhao, et al.
Journal of Cancer (2023) Vol. 14, Iss. 5, pp. 850-873
Open Access | Times Cited: 16
Breaking through: immunotherapy innovations in pleural mesothelioma
Amalia A. Sofianidi, Nikolaos Syrigos, Kevin G. Blyth, et al.
Clinical Lung Cancer (2025)
Open Access
Amalia A. Sofianidi, Nikolaos Syrigos, Kevin G. Blyth, et al.
Clinical Lung Cancer (2025)
Open Access
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment
Santiago Ponce, S. Cedrés, Charles Ricordel, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 9, pp. e007552-e007552
Open Access | Times Cited: 10
Santiago Ponce, S. Cedrés, Charles Ricordel, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 9, pp. e007552-e007552
Open Access | Times Cited: 10
Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy
Federica Torricelli, Benedetta Donati, Francesca Reggiani, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Federica Torricelli, Benedetta Donati, Francesca Reggiani, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream
Luana Calabrò, Giuseppe Bronte, Federica Grosso, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 2
Luana Calabrò, Giuseppe Bronte, Federica Grosso, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 2
Genomic and T cell repertoire biomarkers associated with malignant mesothelioma survival
Muwen Nie, Zhao Sun, Ningning Li, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 19, pp. 1502-1512
Open Access | Times Cited: 1
Muwen Nie, Zhao Sun, Ningning Li, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 19, pp. 1502-1512
Open Access | Times Cited: 1
Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature
Marie-Florence Reveneau, Julien Masliah‐Planchon, Manuel Delgado‐Fernández, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Marie-Florence Reveneau, Julien Masliah‐Planchon, Manuel Delgado‐Fernández, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine
Solfrid Thunold, Eivor Hernes, Saima Jamil Farooqi, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2024)
Open Access | Times Cited: 1
Solfrid Thunold, Eivor Hernes, Saima Jamil Farooqi, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2024)
Open Access | Times Cited: 1
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies
Lauren Chiec, Débora S. Bruno
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10861-10861
Open Access | Times Cited: 1
Lauren Chiec, Débora S. Bruno
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10861-10861
Open Access | Times Cited: 1
BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma
Luisa Bisceglia, Federica Morani, Lara Guerrieri, et al.
Cancer Gene Therapy (2024)
Open Access
Luisa Bisceglia, Federica Morani, Lara Guerrieri, et al.
Cancer Gene Therapy (2024)
Open Access
Transfer learning approach in pre-treatment CT images to predict therapeutic response in advanced malignant pleural mesothelioma
Annarita Fanizzi, Annamaria Catino, Samantha Bove, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Annarita Fanizzi, Annamaria Catino, Samantha Bove, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Real-world outcomes of patients with malignant pleural mesothelioma receiving combination ipilimumab and nivolumab as first- or later line treatment
Sabine Schmid, Lisa Holer, Katrin Gysel, et al.
JTO Clinical and Research Reports (2024) Vol. 5, Iss. 12, pp. 100735-100735
Open Access
Sabine Schmid, Lisa Holer, Katrin Gysel, et al.
JTO Clinical and Research Reports (2024) Vol. 5, Iss. 12, pp. 100735-100735
Open Access
Methylation biomarkers for pleural mesothelioma : from epigenetic landscape analysis to diagnostic assay development
Janah Vandenhoeck
(2024)
Open Access
Janah Vandenhoeck
(2024)
Open Access
Exploring the Expression of the «Dark Matter» of the Genome in Mesothelioma for Potentially Predictive Biomarkers for Prognosis and Immunotherapy
Emanuela Felley‐Bosco
Cancers (2023) Vol. 15, Iss. 11, pp. 2969-2969
Open Access
Emanuela Felley‐Bosco
Cancers (2023) Vol. 15, Iss. 11, pp. 2969-2969
Open Access
